<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell J</journal-id><journal-id journal-id-type="iso-abbrev">Cell J</journal-id><journal-id journal-id-type="publisher-id">Royan Institute</journal-id><journal-title-group><journal-title>Cell Journal (Yakhteh)</journal-title></journal-title-group><issn pub-type="ppub">2228-5806</issn><issn pub-type="epub">2228-5814</issn><publisher><publisher-name>Royan Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">36043403</article-id><article-id pub-id-type="pmc">PMC9428475</article-id><article-id pub-id-type="other">Cell-J-24-353</article-id><article-id pub-id-type="doi">10.22074/cellj.2022.7643</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject><subj-group><subject>Biology</subject><subject>Hearth</subject></subj-group></subj-group></article-categories><title-group><article-title>Cell-Free Treatments: A New Generation of Targeted Therapies for
Treatment of Ischemic Heart Diseases </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Daneshi</surname><given-names>Nahid</given-names></name><degrees>M.D</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bahmaie</surname><given-names>Nazila</given-names></name><degrees>Ph.D</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Esmaeilzadeh</surname><given-names>Abdolreza</given-names></name><degrees>Ph.D</degrees><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref><xref rid="A8" ref-type="aff">8</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><aff id="A1"><label>1</label>School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran</aff><aff id="A2"><label>2</label>Department of Allergy and Immunology, Faculty of Medicine, Graduate School of Health Science, Near East University, Nicosia,
Northern Cyprus, Cyprus</aff><aff id="A3"><label>3</label>Private Baskent Hospital, Nicosia, Northern Cyprus, Cyprus</aff><aff id="A4"><label>4</label>Pediatric Ward, Department of Allergy and Immunology, Near East University Affiliated Hospital, Nicosia, Northern Cyprus, Cyprus</aff><aff id="A5"><label>5</label>Network of Immunity in Infection, Malignancy and Autoimmunity, Universal Scientific Education and Research Network, Tehran, Iran</aff><aff id="A6"><label>6</label>Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran</aff><aff id="A7"><label>7</label>Cancer Gene Therapy Research Centre, Zanjan University of Medical Sciences, Zanjan, Iran</aff><aff id="A8"><label>8</label>Immunotherapy Research and Technology Group, Zanjan University of Medical Sciences, Zanjan, Iran</aff></contrib-group><author-notes><corresp id="cor1">
<label> *Corresponding Address: </label>
<addr-line>P.O.Box: 4513956111</addr-line>
<addr-line>Department of Immunology</addr-line>
<addr-line>School of Medicine</addr-line>
<institution>Zanjan University of Medical Sciences</institution>
<addr-line>Zanjan</addr-line>
<country>Iran</country>
Email:<email>a46reza@zums.ac.ir</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>7</month><year>2022</year></pub-date><volume>24</volume><issue>7</issue><fpage>353</fpage><lpage>363</lpage><history><date date-type="received"><day>28</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>9</month><year>2020</year></date></history><permissions><copyright-statement>Any use, distribution, reproduction or abstract of this publication in any medium,
with the exception of commercial purposes, is permitted provided the original work is properly cited.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative
Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0) License, which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited. </license-p></license></permissions><abstract><p>Although recent progress in medicine has substantially reduced cardiovascular diseases (CVDs)-related mortalities, current
therapeutics have failed miserably to be beneficial for all patients with CVDs. A wide array of evidence suggests that
newly-introduced cell-free treatments (CFTs) have more reliable results in the improvement of cardiac function. The main
regeneration activity of CFTs protocols is based on bypassing cells and using paracrine factors. In this article, we aim to
compare various stem cell secretomes, a part of a CFTs strategy, to generalize their effective clinical outcomes for patients
with CVDs. Data for this review article were collected from 70 published articles (original, review, randomized clinical trials
(RCTs), and case reports/series studies done on human and animals) obtained from Cochrane, Science Direct, PubMed,
Scopus, Elsevier, and Google Scholar) from 2015 to April 2020 using six keywords. Full-text/full-length articles, abstract,
section of book, chapter, and conference papers in English language were included. Studies with irrelevant/insufficient/data,
or undefined practical methods were excluded. CFTs approaches involved in growth factors (GFs); gene-based therapies;
microRNAs (miRNAs); extracellular vesicles (EVs) [exosomes (EXs) and microvesicles (MVs)]; and conditioned media (CM).
EXs and CM have shown more remarkable results than stem cell therapy (SCT). GF-based therapies have useful results as
well as side effects like pathologic angiogenesis. Cell source, cell&#x02032;s aging and CM affect secretomes. Genetic manipulation
of stem cells can change the secretome&#x02019;s components. Growing progression to end stage heart failure (HF), propounds
CFTs as an advantageous method with practical and clinical values for replacement of injured myocardium, and induction
of neovascularization. To elucidate the secrets behind amplifying the expansion rate of cells, increasing life-expectancy, and
improving quality of life (QOL) for patients with ischemic heart diseases (IHDs), collaboration among cell biologist, basic
medical scientists, and cardiologists is highly recommended.</p></abstract><kwd-group><kwd>Cardiovascular Diseases</kwd><kwd>Exosomes</kwd><kwd>Extracellular Vesicles</kwd><kwd>Gene Therapy</kwd><kwd>microRNAs</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>Citation</meta-name><meta-value>Daneshi N, Bahmaie N, Esmaeilzadeh A. Cell-free treatments: a new generation of targeted therapies for treatment of ischemic heart diseases.
Cell J. 2022; 24(7): 353-363. doi: 10.22074/cellj.2022.7643.
This open-access article has been published under the terms of the Creative Commons Attribution Non-Commercial 3.0 (CC BY-NC 3.0).</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>According to the reports of World Health Organization
(WHO), cardiovascular diseases (CVDs) have been
among the leading causes of death worldwide for
the last 15 years. In 2017, they accounted for a
combined total of 17.8 million recorded deaths; being
expected to exceed 22.2 million deaths by 2030 (<xref rid="B1" ref-type="bibr">1</xref>).
Current approaches for treatment of ischemic heart
diseases (IHDs) include procedures restoring blood
flow, pharmacological treatments lessening cardiac
remodeling, cardiovascular surgical interventions, and
various immunopathophysiological strategies inducing
revascularization (<xref rid="B2" ref-type="bibr">2</xref>). Unfortunately, current therapeutic
strategies only postpone the progression from IHDs to
heart failure (HF). In other words, those aforementioned
therapeutic approaches lack the ability to completely
reverse clinical manifestations in patients with CVDs.
Therefore, loss of myocardial tissues with progression
to HF remains as a problematic challenge in IHDs
treatment (<xref rid="B3" ref-type="bibr">3</xref>). Those challenges have encouraged basic
medical scientists to make a borderless and integrative
collaboration by the usage of interdisciplinary frameworks
aimed at seeking for more efficient approaches that are
based on cellular and molecular immunopathophysiology
which play an indispensable role in the microenvironment
of CVDs. Accordingly, stem cell therapy (SCT) is
considered as a recent, and promising strategy in myocyte
replacement after a myocardial infarction (MI) (<xref rid="B4" ref-type="bibr">4</xref>). </p><p>In heart tissue regeneration through SCT, wide array of
stem cells are used aimed at improving clinical outcomes
to increase angiogenesis, decrease pathological cardiac
remodeling, increase left ventricular ejection fraction
(LVEF), amplify regional contractility, decrease scar tissue
and infarct size, improve New York Heart Association
(NYHA) classification, and improve quality of life (QOL) for
patients with CVDs. However, for improving regenerative
functions of an infarcted heart through SCT, there are many
unresolved challenges like: selection of an optimal cell type; possible ambiguities with specification of the cell dose,
route and frequency of administration (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>); possibility of
arrythmogenicity, complex cellular mechanisms of action, and
low number of survived stem cells after transplantation in the
infarct zone (<xref rid="B7" ref-type="bibr">7</xref>). Thus, SCT remains to be determined as the
only responsible source for improvement of cardiac function
(<xref rid="B8" ref-type="bibr">8</xref>). Various cellular and molecular mechanisms have been
proposed to justify the immunobiological properties-derived
clinical applications of SCT, including: i. differentiation of
stem cells into heart muscle cells, ii. differentiation of stem
cells into blood cells, iii. paracrine effects; and, iv. cell fusion
(<xref rid="B7" ref-type="bibr">7</xref>). It has been demonstrated that paracrine mechanisms play
indisputable roles for exacerbating the function of stem cells in
regenerative medicine for treatment of MI. Paracrine effects,
as cell-free treatments (CFTs), have attracted the attention of
researchers because of their clinical potentials in heart tissue
regeneration (<xref rid="B9" ref-type="bibr">9</xref>). In other words, CFTs have shown advantages
through paracrine effects in heart regenerative medicine than
SCT (<xref rid="B10" ref-type="bibr">10</xref>). Not only CFTs-based secretome and paracrine
mechanisms can mimic the beneficial effects of SCT, but they
also can reduce some of limitations and drawbacks regarding
the clinical usages of SCT (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B11" ref-type="bibr">11</xref>). </p><p>In order to design paracrine mechanisms-based therapeutic
approaches, properties of different stem cell-derived
secretomes and agents influencing components of the
secretome are of utmost importance for cell biologists.
Optimization of cells obtained from cell culture medium
and preparation of clinically-effective cells, are prime
examples that should be specified for designation of the most
therapeutic strategies in heart regeneration. So, comprehensive
knowledge and outstanding understanding on molecular
and immunobiological mechanisms of action related to
CFTs-based regenerative activities [particularly geneticallyremodeling exosomes (EXs)], as well as physiological
cardiac remodeling can definitely open promising windows
into recovery of the infarcted area, improvement of QOL,
and increasing life-expectancy for patients with IHDs. Hence,
through more collaborations between physicians, cellular
cellular/molecular biologists, and laboratory scientists,
preclinical and basic medical studies can simplify translation
of laboratory-based data into the clinical settings, decipher
secrets of more accurate medical decisions, make optimal
clinical outcomes, and increase life-expectancy and QOL for
patients with CVDs.</p><p>Here, we aim to summarize different mechanisms
of action and functional roles of CFTs in research
laboratories, highlight the role of data acquired from basic
medical sciences, focus on their therapeutic applications
for treatment of CVDs, and investigate the proficiency and
clinical efficiency of these strategies to improve clinical
outcomes for patients with CVDs.</p><sec><title>Types of cell-free treatment</title><p>The hypothesis, "main regeneration activities of stem cells
are done indirectly through a paracrine manner" is traced back
to the proposal for bypassing cells and simultaneous usage
of supposedly-paracrine factors (<xref rid="B12" ref-type="bibr">12</xref>). Stem cell secretomes
are considered as off-the-shelf therapeutic approaches that
mitigate safety risks, overcome the risks of occlusion in
microvasculature, and refrain from unregulated growth
(particularly for administration of large amounts of viable
cells). In clinical settings, the promising results acquired
from mesenchymal stem cells (MSCs)-derived secretomes
are similar to the results from transplantation of MSCs (<xref rid="B13" ref-type="bibr">13</xref>,
<xref rid="B14" ref-type="bibr">14</xref>). </p><p>In the CFTs method, heart tissues are regenerated
by collaborative functions of growth factors (GFs),
cytokines, microRNAs (miRNAs), involved genes,
EXs, microvesicles (MVs), and conditioned media
(CM)-derived from stem cells. Their presence in
the surrounding tissues leads to the activation of
intrinsic repairing mechanisms (<xref rid="B15" ref-type="bibr">15</xref>). This secretion
regulates several procedures like: myocardial protection,
neovascularization, cardiac remodeling, and induction of
endogenic cardiac stem cells (CSCs) differentiation (<xref rid="B16" ref-type="bibr">16</xref>).
Figure 1 lists the regulatory effects of MSCs secretomes
in heart regeneration (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). </p><p>Conclusively, since heart is not a post-mitotic organ, it
seems that there is an imperative need to a comprehensive
perception from secretomes and paracrine mechanisms to
design new and practical therapeutic approaches aimed at
heart tissue regeneration.</p><fig position="float" id="F1"><label>Fig 1</label><caption><p>The effect of MSCs secretomes in heart tissue regeneration. MSCs
secretomes show their regulatory properties through various paracrine
processes. CMCs; Cardiomyocytes, CPCs; Cardiac progenitor cells, CSCs;
Cardiac stem cells, and MSCs; Mesenchymal stem cells.</p></caption><graphic xlink:href="Cell-J-24-353-g01" position="float"/></fig></sec><sec><title>Extracellular vesicles in ischemic heart diseases</title><p>Extracellular vesicles (EVs) include EXs and MVs. The
components of MVs are 0.1-1 &#x003bc;m in size and they are shed
from the cell surface of normal or damaged cells during
membrane blebbing. EVs can &#x02032;hijack&#x02032; both membrane
components and engulfed cytoplasmic contents. They
contain several structural proteins and lipids that are similar to those in the membranes of the cells from which
they are originated. Those EVs also contain intracellular
proteins, messenger RNAs (mRNAs), regulatory
miRNAs, and intact organelles such as mitochondria (<xref rid="B10" ref-type="bibr">10</xref>).
</p><p>EXs have a diameter of 30-100 nm which are secreted by
different cells through the assimilation of multi-vesicular
bodies within the plasma membrane. They carry complex of
proteins, RNAs and miRNAs, mediating cell signals such as
immune responses, cell survival mechanisms, and intercellular
communications (<xref rid="B19" ref-type="bibr">19</xref>). EXs can be obtained from three groups
of cells, including stem cells [MSCs, CSCs, and embryonic
stem cells (ESCs)]; mature cells present in heart tissues
[cardiomyocytes (CMCs) and fibroblasts]; and from cells
exposed to pathological conditions or genetically-modified
cells (<xref rid="B8" ref-type="bibr">8</xref>). EXs are considered as acceptable therapeutic tools
for heart regenerative medicine which are categorized into
more functional members compared to MVs and apoptotic
bodies. Structurally, the myocardial origin of CMCs-derived
EXs is characterized by their specific protein cargo patterns
which are affected by the cellular microenvironment. EXs
released from cardiosphere derived cells (CDCs) show antiapoptotic and proliferative properties on CMCs (<xref rid="B20" ref-type="bibr">20</xref>). The
therapeutic potency of EXs is usually functionalized in the
presence of a biologically-relevant protein or RNA in the EXs
(<xref rid="B21" ref-type="bibr">21</xref>). In a study on a mouse model of ischemia/reperfusion
(I/R), intravenous injection of MVs on ischemia had led
to reduced myocardial injury, diminished infarct size, and
lessened number of apoptotic CMCs which totally improved
cardiac function (<xref rid="B22" ref-type="bibr">22</xref>).</p><p>The origin of EXs affects their biological behaviours in the
microenvironment. CDCs-derived EXs with miR-146a in a
MI model could improve cardiac function and decrease scar
mass (<xref rid="B11" ref-type="bibr">11</xref>). Administration of MSCs-derived EXs increased
the amount of miR-19a with anti-apoptotic properties in a rat
MI model, which played indisputable roles in activation and
differentiation of endogenous CSCs in the infarcted heart (<xref rid="B8" ref-type="bibr">8</xref>).
Table 1 lists the functions of different particles in stem cellderived Exs and their role in the treatment of IHDs. Table 2
lists a number of EXs that have been recently used in clinical
studies on MI models. In addition, the age of the donor cells
appears to be effective on the composition of secretomes.
Sharma et al. (<xref rid="B23" ref-type="bibr">23</xref>) have reported that neonatal cardiac
progenitor cells-derived conditioned medium (nCPCs-CM)
were more effective than adult CPC-CM (aCPCs-CM).
Surprisingly, nCPCs-CM were more effective than neonatal
CPCs (nCPCs) and nCPC-EX.</p><p>Compared to other cell-based therapies used for heart regeneration, EXs are very stable
and preservable. There is no aneuploidy risk, and also the possibility of immune
rejections after <italic>in vivo</italic> allogeneic administrations is low (<xref rid="B24" ref-type="bibr">24</xref>). Adamiak
et al. (<xref rid="B25" ref-type="bibr">25</xref>) compared the cardiac reparative capabilities of induced pluripotent stem cells
(iPSCs)-derived EXs with iPSCs in a mouse model of reperfused MI. Their results showed
that iPSCs-derived EVs induced superior cardiac repair in vivo compared to iPSCs. In their
study, injections of iPSCs resulted in teratoma formation, whereas injections of
iPSCs-derived EVs were safe. They concluded that iPSCsEVs represented a feasible, and
safer alternative for potential therapeutic applications of EVs in patients with ischemic
myocardial damages.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>The function of different EXs and their effective particles in IHDs</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">EX-derived cells</th><th rowspan="1" colspan="1">EX enriched particles</th><th rowspan="1" colspan="1">Function</th><th rowspan="1" colspan="1">References</th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac endothelial cells</td><td rowspan="1" colspan="1">miR-126 and miR-210</td><td rowspan="1" colspan="1">Proangiogenic</td><td rowspan="1" colspan="1">(26)</td></tr><tr><td align="left" rowspan="1" colspan="1">CPCs</td><td rowspan="1" colspan="1">miR-144</td><td rowspan="1" colspan="1">Cardioprotective</td><td rowspan="1" colspan="1">(26)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">miR-132, miR-146a,</td><td rowspan="1" colspan="1">Proangiogenic</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">miR-210</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">miR-29a</td><td rowspan="1" colspan="1">Anti-fibrotic</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">miR-132, miR-146a,miR-451, miR-210</td><td rowspan="1" colspan="1">Cardioprotective, post-MI neovascularization, and healing of damaged heart tissues</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">CDCs</td><td rowspan="1" colspan="1">miR-146a</td><td rowspan="1" colspan="1">Survival, angiogenesis, and CMCs proliferation</td><td rowspan="1" colspan="1">(15)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">miR-210, miR-132, miR-146a-3p</td><td rowspan="1" colspan="1">Survival</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Angiogenesis</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Sca-1<sup>+</sup>, mouse</td><td rowspan="1" colspan="1">miR-451</td><td rowspan="1" colspan="1">Survival</td><td rowspan="1" colspan="1">(15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac myocytes</td><td rowspan="1" colspan="1">Hsp60</td><td rowspan="1" colspan="1">Induction of CMCs apoptosis</td><td rowspan="1" colspan="1">(27)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypoxic CMCs</td><td rowspan="1" colspan="1">TNF-&#x003b1;</td><td rowspan="1" colspan="1">Triggers cell death in other CMCs</td><td rowspan="1" colspan="1">(27)</td></tr><tr><td align="left" rowspan="1" colspan="1">iPSCs</td><td rowspan="1" colspan="1">miR-21, miR-210</td><td rowspan="1" colspan="1">Cardioprotective</td><td rowspan="1" colspan="1">(27)</td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs</td><td rowspan="1" colspan="1">miR22</td><td rowspan="1" colspan="1">Anti-apoptotic </td><td rowspan="1" colspan="1">(17)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Improvement of ischemic CMCs injuries</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">20S proteasome subunits (PMSA 1-7)</td><td rowspan="1" colspan="1">Cardioprotective</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">miR-21</td><td rowspan="1" colspan="1">Anti-apoptotic</td><td rowspan="1" colspan="1">(27)</td></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>EX; Exosomes, IHD; Ischemic heart disease, CPCs; Cardiac progenitor cells, CMCs; Cardiomyocytes, MSCs; Mesenchymal stem cells, iPSCs; Induced
pluripotent stem cells, and MI; Myocardial infarction.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Comparison of different EXs used as therapeutic tools for different models of IHDs</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Type of EX</th><th rowspan="1" colspan="1">MI model</th><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">Reference</th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">CPCs-derived EX</td><td rowspan="1" colspan="1">Rat</td><td rowspan="1" colspan="1">Improved cardiac function, Less profound cardiac apoptosis, &#x02191; Intracardiac angiogenesis</td><td rowspan="1" colspan="1">(26)</td></tr><tr><td align="left" rowspan="1" colspan="1">SHH-containing EVs</td><td rowspan="1" colspan="1">Murine</td><td rowspan="1" colspan="1">Proangiogenic, anti-apoptotic, and vasculoprotective effects &#x02193; Infarct size</td><td rowspan="1" colspan="1"> (26)</td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs-derived EX</td><td rowspan="1" colspan="1">MIRI mouse model</td><td rowspan="1" colspan="1">Improved CMCs survival &#x02193; Cardiac fibrosis and apoptosis compared to hearts treated with control EX</td><td rowspan="1" colspan="1">(27)</td></tr><tr><td align="left" rowspan="1" colspan="1">MSCs-IPC EX</td><td rowspan="1" colspan="1">Mouse</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">(27)</td></tr><tr><td align="left" rowspan="1" colspan="1">CDCs EX</td><td rowspan="1" colspan="1">Porcine AMI and CMI</td><td rowspan="1" colspan="1">&#x02193;Scarring, halted adverse remodeling, improved LVEF</td><td rowspan="1" colspan="1">(28)</td></tr><tr><td align="left" rowspan="1" colspan="1">Akt-hucMSC derived EX</td><td rowspan="1" colspan="1">Acute MI rat model</td><td rowspan="1" colspan="1">Improved cardiac function, Promoted angiogenesis</td><td rowspan="1" colspan="1">(29)</td></tr><tr><td align="left" rowspan="1" colspan="1">ESCs derived EX</td><td rowspan="1" colspan="1">Acute MI mouse model</td><td rowspan="1" colspan="1">Enhanced neovascularization, augmented cardiac function after MI, reduced fibrosis, promoted CPC and myocyte survival and proliferation</td><td rowspan="1" colspan="1">(30)</td></tr><tr><td align="left" rowspan="1" colspan="1">iPSCs-derived EX </td><td rowspan="1" colspan="1">Reperfused MI in mice</td><td rowspan="1" colspan="1">Improved LV function, reduced apoptosis, promoted angiogenesis, attenuated LV hypertrophy, and iPSCs-EX injection was safe.</td><td rowspan="1" colspan="1">(25)</td></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>EX; Exosomes, IHD; Ischemic heart disease, CPCs; Cardiac progenitor cells, SHH; Sonic hedgehog, EV; Extracellular vesicles, MSCs; Mesenchymal stem cells,
IPC; Ischemic preconditioning, CDC; Cardiosphere derived cells, hucMSCs; Umbilical cord mesenchymal stem cells, iPSC; Induced pluripotent stem cells,
ESC; Embryonic stem cells, iPSCs; Induced pluripotent stem cells, MIRI; Myocardial ischemia-reperfusion injury, AMI; Acute myocardial infarction, CMI;
Chronic myocardial infarction, MI; Myocardial infarction, CMCs; Cardiomyocytes, and LVEF; Left ventricular ejection fraction.</p></fn></table-wrap-foot></table-wrap><p>From cellular aspects, it has been demonstrated that several
cellular procedures indicate potential properties in EVs-based
therapies aimed at regeneration of an infarcted heart. These
aforesaid cellular processes mainly prevent from apoptosis by
inducing autophagy via modulation of AMPK/mTOR, Akt/
mTOR, and Wnt/&#x003b2;-catenin pathways. Hence, clinical usages
of EVs lead to a wide range of improved clinical outcomes
like increased survival rate of CMCs in ischemic lesions,
neovascularization in the peri-infarcted myocardial zone,
restrained pathological remodeling, and regulation of CMCs
function (<xref rid="B14" ref-type="bibr">14</xref>). All in all, it sounds that cells used in SCT-based
approaches now can be genetically altered by GFs, cytokines,
and hypoxia-exposed stem cells under pathologic conditions.
Eventually, secretomes derived from these genetically-altered
stem cells can be used according to the pathophysiological stage
of the patients with CVDs and optimized to treat them (<xref rid="B10" ref-type="bibr">10</xref>).</p></sec><sec><title>Heart tissues-target therapy with exosomes</title><p>Most systemically-injected EXs are accumulated in organs such as the liver, kidneys,
lungs, and bone marrow (BM). Despite the high efficacy observed in concentrated and pure
doses of infused EXs, the therapeutic potentials of EXs mostly depend on their
bio-distribution. Mostlysecreted EXs tend to be less specific to a particular cell type in
the cellular microenvironment. EXs are mostly cleared by macrophages within the
reticulonodular system, limiting their therapeutic applications in clinical trials.
Therefore, the cardioprotective effects and specific/efficient delivery of administered
EXs are not well-established (<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>). To reduce systemic clearance of EXs and increase
their numbers, as well as increase tropism of EXs in target tissues, altering the surface
of these particles by creating ligands is highly recommended. Those ligands bind EXs to
specific molecules or antibodies in target tissues. In an <italic>in vivo</italic> MI
study done by Mentkowski and Lang (<xref rid="B31" ref-type="bibr">31</xref>), engineered CDCs expressing LAMP2-cardyomyocytes
targeting peptide (LAMP2-CMP) on the membranes of secreted Exs, could increase the CMCs
endocytosis potential of CDCs (which are originated from EXs). LAMP2, a membrane protein
on the EXs surface, was fused to CMP (a CMC specific peptide). Intramyocardial injection
of these biologically-engineered EXs showed that they were more likely to be absorbed by
CMCs than the nonengineered types. In comparison with the non-engineered types, these
engineered CDCs could significantly reduce apoptosis, increase the survival rate of CMCs
and induce more cardiac retention.</p><p>Tian et al. (<xref rid="B33" ref-type="bibr">33</xref>) used cyclo (Arg-Gly-Asp-D-Tyr-Lys) peptide [c(RGDyK)] conjugated EXs,
which were called EXs-c(RGDyK) to treat a mouse model of cerebral ischemia. Biologically,
c(RGDyK) is a peptide that has a high affinity for binding to integrin &#x003b1;<sub>v</sub>
&#x003b2;<sub>3</sub> of cerebrovascular endothelial cells after ischemia. The results of their
study showed that intravenous infusion of this engineered EXs strongly suppressed the
inflammatory responses, and lowered cell apoptosis in the lesion area of the cerebral
ischemia.</p><p>As a result, engineered EXs provide a convenient
and effective way to transfer therapeutic materials into
different tissues. These engineered EXs could be enriched
with angiogenic or protective substances to be delivered
to specific target organs and tissues such as the heart in
order to produce effective angiogenesis and increase
CMCs survival for patients with IHDs.</p></sec><sec><title>microRNAs in ischemic heart diseases</title><p>As non-coding RNAs, miRNAs are approximately 22 nucleotides in length, mediating
regulatory effects on post-transcriptional gene expression (<xref rid="B34" ref-type="bibr">34</xref>). They were initially
discovered in <italic>Caenorhabditis elegans </italic>(<italic>C. elegans</italic>) two
decades ago (<xref rid="B35" ref-type="bibr">35</xref>). miRNAs regulate various biological and physiologic pathways such as
differentiation, proliferation, growth, and apoptosis, as well as pathological processes
such as cancer, Alzheimer&#x02019;s and CVDs. miRNAs are found in tissues and body fluids such as
the blood, urine, saliva, plasma and serum (<xref rid="B36" ref-type="bibr">36</xref>). Recently, circulating miRNAs can be used
for diagnosis, prognosis, and therapeutic applications for a wide range of disorders. In
case of MI, it has been speculated that heart tissue undergoes various pathological and
physiological processes such as apoptosis, angiogenesis, tissue perfusion, and fibrosis.
Generally, inhibition or activation of several families of miRNAs, including miRNAs-15,
miRNAs-21, miRNAs-24, miRNAs-29, miRNAs-34, miRNAs-92a, miRNAs-101, miRNAs-133a, and
miRNAs-320 leads to cardiac tissue repair and improved heart function (<xref rid="B37" ref-type="bibr">37</xref>, <xref rid="B38" ref-type="bibr">38</xref>).</p><p>In terms of CVDs, Wang et al. (<xref rid="B39" ref-type="bibr">39</xref>) showed that
knockdown of miR-16-5p increased cell viability and
angiogenesis in human microvascular endothelial cells
(HMVEC), and inhibited cell apoptosis by increasing
insulin receptor substrate 1 (IRS1). Zhao et al. (<xref rid="B40" ref-type="bibr">40</xref>) tried
to clarify the regulatory mechanisms of miR-132 in MIinduced myocardial remodeling. They reported that upregulation of miR-132 increased LVEF and LV fractional
shortening, and inhibited CMCs apoptosis to ameliorate
myocardial remodeling through down-regulation of IL-1&#x003b2;.</p></sec><sec><title>Growth factor therapy in ischemic heart diseases </title><p>Several GFs and cytokines have been used to treat CVDs
in clinical and preclinical studies because of their direct and
distinct effects on several cellular functions such as adhesion,
proliferation, and migration. GFs can induce regenerative
mechanisms that include anti-apoptotic pathways, angiogenic
properties, positive remodeling of the ECM, CMCs
proliferation, and CSC recruitment. The results of most
studies indicate that daily subcutaneous injections of GF
might have cardioprotective effects through up-regulation of
the Akt pathway, and CPC differentiation (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). </p><p>Induction of angiogenesis by GFs during coronary artery
occlusion is an important mechanism that protects heart
tissues against hypoxemic conditions. The process of
angiogenesis is regulated by a various GFs, such as vascular
endothelial growth factor (VEGF), fibroblast growth factor-2
(FGF-2), and platelet-derived growth factor (PDGF). VEGF
is a major initiator of angiogenesis and recruitment factor for
endothelial cells; FGF-2 is a mitogen of various cell types,
recruitment factor for pericytes, and a producer of the ECM.
PDGF is a recruitment factor for smooth muscle cells and a
maturation factor for new vessels, playing an important role
in angiogenic processes. As a result, these processes lead the
microenvironment toward increased tissue perfusion, reduced
inflammation and fibrosis, and ultimate improvement in heart
muscle performance (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B42" ref-type="bibr">42</xref>). </p><p>Several GFs have been used to treat CVDs.
Thavapalachandran et al. (<xref rid="B43" ref-type="bibr">43</xref>) in their experimental study
evaluated the therapeutic effects of recombinant human
platelet-derived growth factor-AB (rhPDGF-AB) protein in
a clinically-relevant porcine model of myocardial ischemiareperfusion injury (MIRI). They demonstrated that infusion of
rhPDGF-AB promoted post-MI cardiac repair by altering the
mechanics of the infarcted scar, being resulted in improved
LVEF, myocardial contractility, and increased survival rate,
as well as decreased ventricular arrhythmias. Furthermore,
injection of stromal-derived factor-1 (SDF-1/CXCR4) in the
myocardia of patients with IHDs was reported to be a safe
and experimentally-feasible approach. Patients who received
the highest doses (15 mg and 30 mg) of SDF-1 had shown
improvement in QOL, the six-minute walking distance test,
and NYHA class (<xref rid="B44" ref-type="bibr">44</xref>). </p><p>According to the reported side effects due to
administration of high or inappropriate dosages of certain
cytokine/GFs (like organization of aberrant and perforated
vessels, hypotension, and tumour angiogenesis), there
is an imperative need for further investigations on the
proper clinical usage of GFs and cytokines for treatment
of patients with CVDs (<xref rid="B18" ref-type="bibr">18</xref>).</p></sec><sec><title>Conditioned media in ischemic heart diseases</title><p>As described earlier, secretomes consist of proteins,
miRNAs, GFs, anti-oxidants, proteasomes, and EXs
secreted by stem cells. Literally, those culture media which
are conditioned by secretomes are called CM. A variety
of paracrine factors, including VEGF, hepatocyte growth
factor (HGF), insulin-like growth factor-1 (IGF-1), IGF-2
and SDF-1, are secreted into the cell culture medium during
the cell culture processes. These factors are associated with
physiological and pathophysiological processes like cell
proliferation, apoptosis, inflammation, neovascularization,
MI, angiogenesis, and fibrosis. It is presumed that addition of
secretomes to the cell culture media of the damaged organs
increases metabolic activities, oxygen supply, and remodeling
the ECM in order to ultimately prevent from increased organ
damage (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>). </p><p>In case of CVDs, CM can be used to induce clinicallyadvantageous effects on target tissues. For example, either
CDC-derived CM or MSC-derived CM have the capability
to increase the survival potential of CMCs against hypoxia
(<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B19" ref-type="bibr">19</xref>). Secretomes are the most functional unit of stem
cells and EXs play an indispensable role in improving
their therapeutic manifestation; however, Sharma et al.
(<xref rid="B23" ref-type="bibr">23</xref>) reported that sole administration of EXs does not
suffice and CM is needed for maximum clinical benefit.
In addition, they reported that division of CM into EXs
and EX-free fractions diminishes its capacity to recover
myocardial function. MVs and CM derived from stem
cells have the same pro-regenerative potentials as
infusion of intact cells (<xref rid="B10" ref-type="bibr">10</xref>) which can replace the cells in
SCT. Fortunately, the allogeneic CM method lacks ethical
controversies and immune rejection. Then, it appears to be
a perfect, and promising solution for immediate clinical
applications with the ability to minimize the amount of
surgeries invasiveness (<xref rid="B47" ref-type="bibr">47</xref>). Table 3 shows the effects
of CMs that are originated from different stem cells in
animal models of IHDs.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Comparison of different CMs for treatment of IHD models</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Source of CM</th><th rowspan="1" colspan="1">Animal model</th><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">Reference</th></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">hADSCs</td><td rowspan="1" colspan="1">SCID and</td><td rowspan="1" colspan="1">Improved cardiac function</td><td rowspan="1" colspan="1">(48)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">C57BL/6 mice model of MI</td><td rowspan="1" colspan="1">&#x02193; Infarct size</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191; Reparative angiogenesis</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193; CMCs apoptosis (The observed effects of ADSCs application on the first three mentioned outcomes were superior to those reported from ADSC-CM.)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Human STRO-3-mesenchymal precursor cells</td><td rowspan="1" colspan="1">Athymic nude rat model of MI</td><td rowspan="1" colspan="1">&#x02191; Ventricular function</td><td rowspan="1" colspan="1">(48)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193; Ventricular dilatation and infarct size</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191; Neovascularization</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Human embryonic stem cell-derived MSCs</td><td rowspan="1" colspan="1">Porcine model of MI</td><td rowspan="1" colspan="1">&#x02191; Capillary density</td><td rowspan="1" colspan="1">(48)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193; Infarct size</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191; Myocardial performance</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Porcine peripheral blood endothelial progenitor cells</td><td rowspan="1" colspan="1">Porcine model of MI</td><td rowspan="1" colspan="1">&#x02191; Angiogenesis&#x02191; CMCs remodeling and contractility</td><td rowspan="1" colspan="1">(48)</td></tr><tr><td align="left" rowspan="1" colspan="1">Human MSCs</td><td rowspan="1" colspan="1">Porcine model of MI</td><td rowspan="1" colspan="1">&#x02191; Myocardial capillary density</td><td rowspan="1" colspan="1">(45)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193; MI size, and preserved systolic and diastolic performance</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SHED-CM</td><td rowspan="1" colspan="1">Mouse model of I/R</td><td rowspan="1" colspan="1">&#x02193; MI size</td><td rowspan="1" colspan="1">(47)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193; Apoptosis</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02193;Inflammatory cytokine levels of TNF-&#x003b1;, IL-6, and IL-&#x003b2;</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191; Cardiac function</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191;Survival of cardiac myocytes in response to hypoxia</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">nCPCs</td><td rowspan="1" colspan="1">Rodent model of MI</td><td rowspan="1" colspan="1">&#x02191; Recovering cardiac function</td><td rowspan="1" colspan="1">(23)</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191; Stimulation of neovascularization</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#x02191; Myocardial remodeling</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hypoxic-ADMSCs</td><td rowspan="1" colspan="1">Rat model of MI</td><td rowspan="1" colspan="1">&#x02193; Infarct size, apoptosis index, and apoptosis related proteins</td><td rowspan="1" colspan="1">(49)</td></tr><tr><th colspan="4" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>HD; Ischemic heart disease, CM; Conditioned media, hADSCs; Human adipose tissue-derived stem cells, MSCs; Mesenchymal stem cells, ADMSCs: Adipose
tissue-derived mesenchymal stem cells; SHED; Stem cells from human exfoliated deciduous teeth, CPCs; Cardiac progenitor cells, MI; Myocardial infarction,
CMCs; Cardiomyocytes, I/R; Ischemia/reperfusion, ESCs; Embryonic stem cells, and nCPCs; Neonatal CPCs.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Gene therapy in ischemic heart diseases
</title><p>Although several GFs have been used to stimulate
new vessel formation after MI, none of them could
achieve significant results in phase I/II clinical trials
of heart regeneration. A clinically-acceptable solution
to overcome this problematic challenge is gene therapy
that shows desired clinical outcomes. To date, plasmids
with adenovirus vectors delivering VEGF, FGF and
HGF for treatment of patients with severe coronary
artery diseases (CADs) and MI have been the focus of
investigation in several randomized controlled trials
(RCTs). Researchers proposed that the combination of gene-based therapies with SCT could significantly
improve clinical outcomes in heart regeneration
medicine (<xref rid="B50" ref-type="bibr">50</xref>). </p><p>Gene-based therapies are techniques that use biological
carriers to simplify the insertion and expression of a
therapeutic gene in target cells (<xref rid="B51" ref-type="bibr">51</xref>), in order to induce or
inhibit synthesis of specific proteins and alter the structure
and function of the cells in target tissues (<xref rid="B52" ref-type="bibr">52</xref>).</p><p>Gene-based therapies mainly refer to the utilization
of genetically-altered cells as carriers for the genes and
plasmids aimed at transferring these target genes to
damaged heart tissues for treatment of patients with IHDs.
These genetic changes in cells go back to the fact that they
are measured out to increase the expressions of specific
genes, GFs, and cytokines, affecting immunobiological
processes such as angiogenesis, proliferation and
differentiation of CSCs, apoptosis, remodeling, and
ventricular function (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>).</p><p>Various carriers used to transfer the desired genes to the
target cells include: i. Plasmid carriers for transportation
of naked DNA, ii. Viral vectors such as Adenoviruses,
Adeno-associated viruses, Retroviruses, and Lentiviruses
(<xref rid="B51" ref-type="bibr">51</xref>); and iii. Gene-modified cells (<xref rid="B52" ref-type="bibr">52</xref>). Gene-modified
cells with the ability to overexpress the transgenes act as
transgene carriers, leading to reinforced/desired levels of
therapeutic proteins in target tissues (<xref rid="B52" ref-type="bibr">52</xref>).</p><p>Despite substantial progress in novel therapeutics, there are still several types of
disorders especially those which have not an efficient and successful treatment, leading
basic medical scientists and clinical specialists toward novel therapeutic strategies like
gene-based therapies. For instance, modified BMMSCs that overexpress
<italic>IL-35</italic> gene in an Imiquimodinduced psoriasis-like mouse model will most
likely become an effective therapeutic approach for the worldwide problem of psoriasis
(<xref rid="B53" ref-type="bibr">53</xref>). Lin et al. (<xref rid="B54" ref-type="bibr">54</xref>) investigated whether overexpression of the <italic>IGF-1</italic>
gene could enhance BM-derived stem cell (BMSC) viability, migration, anti-apoptotic, and
protective effects of CMCs in an acute MI (AMI) rat model. They reported that BMSCs that
overexpressed <italic>IGF-1</italic> gene called BMSCs-IGF-1 could significantly rescue
cardiomyoblasts from hypoxia-induced apoptosis, preserve cell viability under hypoxic
conditions and reduce the infarct volume. Su et al. (<xref rid="B55" ref-type="bibr">55</xref>) in their study on an AMI rat
model, loaded Adenoviruses that carried the <italic>SDF-1&#x003b1;</italic> gene onto microbubble
carriers by ultrasound targeted destruction of these microbubbles. The results of their
study suggested that ultrasoundmediated transduction of the exogenous
<italic>SDF-1&#x003b1;</italic> genes into the AMI rats could effectively promote the homing of
endogenous BMSCs into the infarcted heart. </p><p>Figure 2 shows a schematic presentation of novel
strategies recruited by CFTs aimed at treatment of patients
with CVDs.
</p><fig position="float" id="F2"><label>Fig 2</label><caption><p>Schematic presentation of novel therapeutic strategies for CVDs.
CFTs includes GFs, gene-based therapies, miRNAs, EVs, and CM. EX and
CM usually have more remarkable results than stem cell therapy. CVDs;
Cardiovascular diseases, CFTs; Cell-free treatments, CSCs; Cardiac stem
cells, GF; Growth factor, miRNAs; microRNAs, EVs; Extracellular vesicles, EX;
Exosomes, CM; Conditioned media, and MSCs; Mesenchymal stem cells.</p></caption><graphic xlink:href="Cell-J-24-353-g02" position="float"/></fig></sec><sec><title>Route, time, and dosage of cell-free treatment
administration</title><p>CFTs-based therapy for heart regeneration is
administered by intravenous, intra-arterial, intramuscular,
or intramyocardial injections of several recombinant angiopeptides such as VEGF, FGF, and HGF (<xref rid="B56" ref-type="bibr">56</xref>). To be more
precise, for having an ideal route of administration of
CFTs (GFs)-based therapies, time- and dose-dependent
function/efficacy of recruited genes can be considered as
a major hindrance for heart regeneration. Bauz&#x000e1; et al. (<xref rid="B57" ref-type="bibr">57</xref>)
investigated whether optimized doses of high mobility group
box 1 (HMGB1) would promote angiogenesis signaling, and
expression of specific regenerative genes in sheep with acute
MI. They reported that intramyocardial injection of high-dose
(250 &#x003bc;g) HMGB1 had induced angio/arteriogenesis, reduced
the infarct size, and improved LV function two months posttreatment.</p><p>Although delivery of angiogenic factors has the potential abilities to stimulate
formation of new blood vessels both <italic>in vivo</italic> and <italic>in
vitro</italic>, there are some limitations that should not be underestimated. Those
limitations include the explosive or uncontrolled release of GFs that leads to high
toxicity; decreased half-life of GFs; and elevated cost for purified GFs. One strategy for
overcoming these challenges is delivery of the gene of the same factor in the cells for
producing the required angiogenic GFs (<xref rid="B58" ref-type="bibr">58</xref>). Gene delivery strategies will be discussed in
the following paragraphs.</p><p>Direct surgical injection, catheter-based intracardiac or
intracoronary injections, pericardial delivery, the V-focus
system, and surgical delivery strategies are used for gene transferring and gene delivery to the myocardium.
Although there is no unique delivery system or a virus
serotype specifically-optimized for cardiac orientation
that lacks simultaneous expression in other tissues. The
molecular cardiac surgery with recirculating delivery
(MCARD) vector-mediated gene is undoubtedly
considered as one of the most promising gene transfer
systems, providing very high expression levels with low
morbidity, diminished immune responses, and minimal
simultaneous expression (<xref rid="B59" ref-type="bibr">59</xref>). </p><p>Selection of the most proper transgenes, the most
efficient routes of gene delivery, the type and quality
of these recruited vectors for gene-based therapies, and
dosage are all determining factors for optimal therapeutic
outcomes in gene-based therapies of CVDs (<xref rid="B60" ref-type="bibr">60</xref>). </p><p>A meta-analysis conducted by Yang et al. (<xref rid="B61" ref-type="bibr">61</xref>) for a
systematic review of the efficacy of EVs on MI in both
small and large animals did not show any significant
associations between efficacy and type of stem cells,
ligation-to-injection interval, route of delivery, dosage,
and follow-up period. However, Liu et al. (<xref rid="B62" ref-type="bibr">62</xref>) performed a
meta-analysis to systematically review the efficacy of EVs
in preclinical acute kidney injury (AKI) rodent models.
They reported that the route of delivery, dosage, and cell
origin of EVs were independent factors that influenced
clinical effects of the EVs. For achieving maximum
efficacy without adverse effects in EVs-based therapies,
determining the optimal dosage, appropriate time window
for administration of EXs, number of repeated dosages,
and route of administration are considered as the most
important issues to be resolved (<xref rid="B63" ref-type="bibr">63</xref>).</p></sec><sec><title>Clinical trials of cell-free treatment in ischemic
heart diseases</title><p>Effective results acquired from preclinical studies have encouraged scientists to
continue experimental studies toward clinical trials. In recent decades, many clinical
trials have been conducted aimed at CFTs-based therapies for patients with IHDs. These
studies focused on the clinical usages of angiogenic genes such as <italic>VEGF, FGF,
HGF</italic>, developmental endothelial locus-1 (<italic>DEL1</italic>), and
<italic>SDF</italic>. Meng et al. (<xref rid="B64" ref-type="bibr">64</xref>) performed intracoronary transplantation of
Adenoviruses that carried the <italic>HGF</italic> gene (Ad<italic>-HGF</italic>) in
patients with CADs. They concluded that long-term administration of
Ad-<italic>HGF</italic> was safe that did not cause any adverse reactions or unwanted
clinical manifestations (like tumors, prolonged fever, arrhythmia, and retinal vessel
anomalies). The results of their study showed that intracoronary transplantation of
Ad-<italic>HGF</italic> efficiently improved echocardiographic EF at the 36-month
follow-up compared to the results acquired from baseline levels. </p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>The most important clinical trials with different GFs and gene therapies in patients with IHDs</p></caption><table frame="hsides" rules="groups"><tbody><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr><tr><th rowspan="1" colspan="1">Author and year of publication</th><th rowspan="1" colspan="1">Vector or GF</th><th rowspan="1" colspan="1">Patients</th><th rowspan="1" colspan="1">Outcome measurements</th><th rowspan="1" colspan="1">Results</th></tr><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr><tr><td align="left" rowspan="1" colspan="1">Anttila et al. (67), 2020</td><td rowspan="1" colspan="1">Epicardial injection of AZD8601 (VEGF-A165 mRNA formulated in biocompatible citrate-buffered saline and optimized for high-efficiency VEGF-A expression with minimal innate immune response)</td><td rowspan="1" colspan="1">24 patients with stable CADs and moderately decreased LVEF (30%-50%) who were undergoing coronary artery bypass graft surgery</td><td rowspan="1" colspan="1">The safety and tolerability of AZ8601, effect of AZD8601 on regional and global stress myocardial blood flow, LV end-diastolic volume, LV end-systolic volume, and LVEF, regional myocardial wall motion, NYHA class, change in troponin T and NT-proBNP levels in six months</td><td rowspan="1" colspan="1">Ongoing clinical trial</td></tr><tr><td align="left" rowspan="1" colspan="1">Greenberg et al. (68), 2016</td><td rowspan="1" colspan="1">Intracoronary adeno-associated virus 1 /sarcoplasmic/endoplasmic reticulum Ca<sup>2</sup><sup>+</sup>-ATPase</td><td rowspan="1" colspan="1">250 patients who had NYHA class II-IV HF and LVEF&#x02264;35%</td><td rowspan="1" colspan="1">Time to recurrent events, defined as hospital admission because of HF or ambulatory treatment for worsening HF in 12 months</td><td rowspan="1" colspan="1">No evidence of improvement in the clinical course and outcome</td></tr><tr><td align="left" rowspan="1" colspan="1">Chung et al. (69), 2015</td><td rowspan="1" colspan="1">Endomyocardial injection of plasmid SDF-1</td><td rowspan="1" colspan="1">93 subjects with IHF on stable guideline-based medical therapy and LVEF &#x02264;40%</td><td rowspan="1" colspan="1">Safety, efficacy, LV functional and structural measures were assessed</td><td rowspan="1" colspan="1">Attenuating LV remodeling and improving EF. Demonstrated safety</td></tr><tr><td align="left" rowspan="1" colspan="1">Penn et al. (70), 2013</td><td rowspan="1" colspan="1">Endomyocardial injection of JVS-100 (a DNA plasmid encoding human SDF-1)</td><td rowspan="1" colspan="1">17 subjects with ischemic cardiomyopathy, NYHA class III HF, and EF &#x02264;40% on stable medical therapy</td><td rowspan="1" colspan="1">Major adverse cardiac events, QOL, NYHA class, six-minute walking distance, single photon emission computed tomography, NT-proBNP and safety over 12 months</td><td rowspan="1" colspan="1">All of the cohorts demonstrated improvements in six-minute walking distance, QOL, and NYHA class. The primary safety end point was met</td></tr><tr><th colspan="5" rowspan="1">
<hr/>
</th></tr></tbody></table><table-wrap-foot><fn><p>IHD; Ischemic heart disease, GFs; Growth factors, CADs; Coronary artery diseases, NYHA: New York Heart Association, IHF; Ischemic heart failure, NTproBNP; N-terminal pro b-type natriuretic peptide, HF; Heart failure, QOL; Quality of life, EF; Ejection fraction, LV; Left ventricle, SDF-1; Stromal-derived
factor-1, LVEF; Left ventricular ejection fraction, and VEGF-A; Vascular endothelial growth factor A.</p></fn></table-wrap-foot></table-wrap><p>Gross et al. (<xref rid="B65" ref-type="bibr">65</xref>) conducted a randomized, prospective,
double-blind, and placebo-controlled clinical trial
(SITAGRAMI) that included 174 patients with acute MI.
Participants were treated with placebo (control group)
or a 1:1 ratio of granulocyte-colony stimulating factor
(G-CSF) plus sitagliptin (case group). The results of
their study that included a 4.5 year follow-up, showed
no significant differences in the incidence rate of major
adverse cardiac and cerebrovascular events (MACCE)
between both control and case groups. Treatment with
sitagliptin did not have any significant effects on the
clinical outcomes of patients with MI.</p><p>Kuku&#x00142;a et al. (<xref rid="B66" ref-type="bibr">66</xref>) conducted a double-blind clinical trial
(NCT00620217) on 52 patients with CADs, who received
intramyocardial injections of VEGF-A165/bFGF plasmid
into the ischemic regions of the heart tissues. The control
group received a placebo plasmid. The results of the 10
year follow-up showed that this vector was also safe and
there was no evidence of increase in the prevalence of
death or malignancies. They indicated that the incidence
of stroke, MI, and cardiovascular-related mortalities were
similar between both control and case groups.</p><p>Table 4 summarizes the most important clinical trials
that used various GFs and gene-based therapies for
patients with IHDs. </p><p>However, our search results could not find any
reasonable clinical usage of EXs, CM, and miRNAs
among current clinical trials of EVs for patients with
IHDs. Although CFTs-based strategies are promising
approaches for treatment of patients with CVDs, more
preclinical studies are needed to evaluate the efficacy of
CFTs as effective therapeutic approaches for IHDs. These
studies should particularly be conducted with large animal
models of IHDs, enabling progress toward more efficient
and productive clinical trials. </p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Despite substantial progress in the prognosis, diagnosis,
and treatment of diseases, CVDs-related morbidities
and mortalities still remain high. Hence, scientists are
encouraged toward more practical methods to obtain better
clinical outcomes. In this context, clinical applications of
stem cell-derived secretomes as a missing piece in the
puzzle of CVDs target therapy can be considered as off-theshelf methods with controlled and predictable outcomes,
decreased adverse effects, and reduced constrains of SCT.
Neovascularization, differentiation, and proliferation
of new CSCs are significant features that should not be
underestimated for heart regenerative medicine, which may
provide effective outcomes for treatment of patients with
IHDs, and increase LV contractility in patients with HF.
</p><p>According to the results acquired from current studies,
EXs and CM have shown more practical effects among the
various types of CFTs, as well as when compared to SCT.
The usage of genetically-modified cell culture medium
through neonatal cell-derived CM, and the components
present in Exs, and CM allow us to expect cost-effective
and optimized results for treatment of various clinical
stages in CVDs. Despite the successful results acquired
from clinical studies done on CVDs models, adverse
effects such as hypotension, tumor angiogenesis, severe
inflammatory reactions, arrhythmia, off-target responses,
and poor gene transfer efficiency have been reported,
complicating clinical applications of GF-based therapies
in patients with CVDs. Although a myriad of preclinical
and laboratory studies have used GFs and gene-based
therapies for improvement of cardiovascular performance
in patients with IHDs, they have failed to achieve much
success in improving cardiac function and halting the MI
process. </p><p>Totally, due to less adverse effects, CFTs can hopefully
pave the way for providing more promising therapeutic
approaches for patients with CVDs, reducing IHDsrelated mortalities and morbidities rates, as well as
diminishing hospitalization expenses for patients and the
health system. </p><p>CFT, with a broad spectrum of profound regulatory
effects on clinical outcomes of patients with CVDs is still
in its infancy. Further investigations aimed at elimination
of the ambiguities related to the clinical applications of
this recently-introduced method are highly recommended
for achievement of beneficial effects of CFTs. In order
to reach this purpose, additional preclinical and clinical
studies, and collaboration among cellular and molecular
biologists, clinical laboratory scientists, immunobiologists,
gene and cell therapists, clinical specialists, diseasesspecific biomarker scientists, cardiologists, medical
biotechnologists, and health science coordinators are
unquestionably needed.</p></sec></body><back><ack><title>Acknowledgements</title><p>There are no financial support, and conflicts of interest
in this study.</p></ack><bio id="d64e1087"><title>Authors&#x02019; Contributions</title><p>A.E.; Supervision, project corresponding, and
verification of the last version before submission. A.E.,
N.B.; Contribution to conceptualization, validation, and
formal analysis. N.B.; Designation of main methodology,
search strategy, academic/scientific/grammatical revision
for important intellectual content, preparation, and main
designation of the final draft of the manuscript. N.D., N.B.;
Major conception, data extraction, and data interpretation.
N.D.; Data gathering and preparation of first draft of
manuscript, visualization, image/table designation. All of
the authors attest to the validity and legitimacy of data,
receiving an electronic copy of the final version, and
published version of the manuscript. </p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Virani</surname><given-names>SS</given-names></name>
<name><surname>Alonso</surname><given-names>A</given-names></name>
<name><surname>Benjamin</surname><given-names>EJ</given-names></name>
<name><surname>Bittencourt</surname><given-names>MS</given-names></name>
<name><surname>Callaway</surname><given-names>CW</given-names></name>
<name><surname>Carson</surname><given-names>AP</given-names></name>
<etal/>
</person-group><article-title>Heart disease and stroke statistics-2020 update: a report from the american heart association</article-title><source>Circulation</source><year>2020</year><volume>141</volume><issue>9</issue><fpage>e139</fpage><lpage>e596</lpage><pub-id pub-id-type="pmid">31992061</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Duan</surname><given-names>B</given-names></name>
</person-group><article-title>Concise review: harnessing iPSC-derived cells for ischemic heart disease treatment</article-title><source>J Transl Int Med</source><year>2020</year><volume>8</volume><issue>1</issue><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">32435608</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cambria</surname><given-names>E</given-names></name>
<name><surname>Steiger</surname><given-names>J</given-names></name>
<name><surname>G&#x000fc;nter</surname><given-names>J</given-names></name>
<name><surname>Bopp</surname><given-names>A</given-names></name>
<name><surname>Wolint</surname><given-names>P</given-names></name>
<name><surname>Hoerstrup</surname><given-names>SP</given-names></name>
<etal/>
</person-group><article-title>Cardiac regenerative medicine: the potential of a new generation of stem cells</article-title><source>Transfus Med Hemother</source><year>2016</year><volume>43</volume><issue>4</issue><fpage>275</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">27721703</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esmaeilzadeh</surname><given-names>A</given-names></name>
<name><surname>Daneshi</surname><given-names>N</given-names></name>
<name><surname>Erfanmanesh</surname><given-names>M</given-names></name>
</person-group><article-title>Evaluation of methods of cultivation, processing and improving of stem cell differentiation into cardiomyocytes</article-title><source>Journal of Laboratory and Diagnosis</source><year>2017</year><volume>8</volume><issue>34</issue><fpage>39</fpage><lpage>47</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sasse</surname><given-names>S</given-names></name>
<name><surname>Skorska</surname><given-names>A</given-names></name>
<name><surname>Lux</surname><given-names>CA</given-names></name>
<name><surname>Steinhoff</surname><given-names>G</given-names></name>
<name><surname>David</surname><given-names>R</given-names></name>
<name><surname>Gaebel</surname><given-names>R</given-names></name>
</person-group><article-title>Angiogenic potential of bone marrow derived CD133+ and CD271+ intramyocardial stem cell trans- plantation post MI</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>78</fpage><lpage>78</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turner</surname><given-names>D</given-names></name>
<name><surname>Rieger</surname><given-names>AC</given-names></name>
<name><surname>Balkan</surname><given-names>W</given-names></name>
<name><surname>Hare</surname><given-names>JM</given-names></name>
</person-group><article-title>Clinical-based cell therapies for heart disease-current and future state</article-title><source>Rambam Maimonides Med J</source><year>2020</year><volume>11</volume><issue>2</issue><fpage>e0015</fpage><lpage>e0015</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanganalmath</surname><given-names>SK</given-names></name>
<name><surname>Bolli</surname><given-names>R</given-names></name>
</person-group><article-title>Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions</article-title><source>Circ Res</source><year>2013</year><volume>113</volume><issue>6</issue><fpage>810</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">23989721</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singla</surname><given-names>DK</given-names></name>
</person-group><article-title>Stem cells and exosomes in cardiac repair</article-title><source>Curr Opin Pharmacol</source><year>2016</year><volume>27</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">26848944</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wernly</surname><given-names>B</given-names></name>
<name><surname>Mirna</surname><given-names>M</given-names></name>
<name><surname>Rezar</surname><given-names>R</given-names></name>
<name><surname>Prodinger</surname><given-names>C</given-names></name>
<name><surname>Jung</surname><given-names>C</given-names></name>
<name><surname>Podesser</surname><given-names>BK</given-names></name>
<etal/>
</person-group><article-title>Regenerative cardiovascular therapies: stem cells and beyond</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>6</issue><fpage>1420</fpage><lpage>1420</lpage></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ratajczak</surname><given-names>MZ</given-names></name>
<name><surname>Kucia</surname><given-names>M</given-names></name>
<name><surname>Jadczyk</surname><given-names>T</given-names></name>
<name><surname>Greco</surname><given-names>NJ</given-names></name>
<name><surname>Wojakowski</surname><given-names>W</given-names></name>
<name><surname>Tendera</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Pivotal role of paracrine effects in stem cell therapies in regenerative medicine: can we translate stem cell-secreted paracrine factors and microvesicles into better therapeutic strategies?</article-title><source>Leukemia</source><year>2012</year><volume>26</volume><issue>6</issue><fpage>1166</fpage><lpage>1173</lpage><pub-id pub-id-type="pmid">22182853</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Prathipati</surname><given-names>P</given-names></name>
<name><surname>Nandi</surname><given-names>SS</given-names></name>
<name><surname>Mishra</surname><given-names>PK</given-names></name>
</person-group><article-title>Stem cell-derived exosomes, autophagy, extracellular matrix turnover, and mirnas in cardiac regeneration during stem cell therapy</article-title><source>Stem Cell Rev Rep</source><year>2017</year><volume>13</volume><issue>1</issue><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">27807762</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cambria</surname><given-names>E</given-names></name>
<name><surname>Pasqualini</surname><given-names>FS</given-names></name>
<name><surname>Wolint</surname><given-names>P</given-names></name>
<name><surname>G&#x000fc;nter</surname><given-names>J</given-names></name>
<name><surname>Steiger</surname><given-names>J</given-names></name>
<name><surname>Bopp</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Translational cardiac stem cell therapy: advancing from firstgeneration to next-generation cell types</article-title><source>NPJ Regen Med</source><year>2017</year><volume>2</volume><fpage>17</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">29302353</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tsao</surname><given-names>CR</given-names></name>
<name><surname>Liao</surname><given-names>MF</given-names></name>
<name><surname>Wang</surname><given-names>MH</given-names></name>
<name><surname>Cheng</surname><given-names>CM</given-names></name>
<name><surname>Chen</surname><given-names>CH</given-names></name>
</person-group><article-title>Mesenchymal stem cell derived exosomes: a new hope for the treatment of cardiovascular disease?</article-title><source>Acta Cardiol Sin</source><year>2014</year><volume>30</volume><issue>5</issue><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">27122816</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harrell</surname><given-names>CR</given-names></name>
<name><surname>Fellabaum</surname><given-names>C</given-names></name>
<name><surname>Jovicic</surname><given-names>N</given-names></name>
<name><surname>Djonov</surname><given-names>V</given-names></name>
<name><surname>Arsenijevic</surname><given-names>N</given-names></name>
<name><surname>Volarevic</surname><given-names>V</given-names></name>
</person-group><article-title>Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome</article-title><source>Cells</source><year>2019</year><volume>8</volume><issue>5</issue><fpage>467</fpage><lpage>467</lpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khanabdali</surname><given-names>R</given-names></name>
<name><surname>Rosdah</surname><given-names>AA</given-names></name>
<name><surname>Dusting</surname><given-names>GJ</given-names></name>
<name><surname>Lim</surname><given-names>SY</given-names></name>
</person-group><article-title>Harnessing the secretome of cardiac stem cells as therapy for ischemic heart disease</article-title><source>Biochem Pharmacol</source><year>2016</year><volume>113</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">26903387</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mirotsou</surname><given-names>M</given-names></name>
<name><surname>Jayawardena</surname><given-names>TM</given-names></name>
<name><surname>Schmeckpeper</surname><given-names>J</given-names></name>
<name><surname>Gnecchi</surname><given-names>M</given-names></name>
<name><surname>Dzau</surname><given-names>VJ</given-names></name>
</person-group><article-title>Paracrine mechanisms of stem cell reparative and regenerative actions in the heart</article-title><source>J Mol Cell Cardiol</source><year>2011</year><volume>50</volume><issue>2</issue><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">20727900</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallina</surname><given-names>C</given-names></name>
<name><surname>Turinetto</surname><given-names>V</given-names></name>
<name><surname>Giachino</surname><given-names>C</given-names></name>
</person-group><article-title>A new paradigm in cardiac regeneration: the mesenchymal stem cell secretome</article-title><source>Stem Cells Int</source><year>2015</year><volume>2015</volume><fpage>765846</fpage><lpage>765846</lpage><pub-id pub-id-type="pmid">26074978</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ranganath</surname><given-names>SH</given-names></name>
<name><surname>Levy</surname><given-names>O</given-names></name>
<name><surname>Inamdar</surname><given-names>MS</given-names></name>
<name><surname>Karp</surname><given-names>JM</given-names></name>
</person-group><article-title>Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease</article-title><source>Cell Stem Cell</source><year>2012</year><volume>10</volume><issue>3</issue><fpage>244</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">22385653</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>P</given-names></name>
<name><surname>Tian</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
</person-group><article-title>New strategies for improving stem cell therapy in ischemic heart disease</article-title><source>Heart Fail Rev</source><year>2016</year><volume>21</volume><issue>6</issue><fpage>737</fpage><lpage>752</lpage><pub-id pub-id-type="pmid">27459850</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carotenuto</surname><given-names>F</given-names></name>
<name><surname>Teodori</surname><given-names>L</given-names></name>
<name><surname>Maccari</surname><given-names>AM</given-names></name>
<name><surname>Delbono</surname><given-names>L</given-names></name>
<name><surname>Orlando</surname><given-names>G</given-names></name>
<name><surname>Di Nardo</surname><given-names>P</given-names></name>
</person-group><article-title>Turning regenerative technologies into treatment to repair myocardial injuries</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><issue>5</issue><fpage>2704</fpage><lpage>2716</lpage><pub-id pub-id-type="pmid">31568640</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Toh</surname><given-names>WS</given-names></name>
<name><surname>Lai</surname><given-names>RC</given-names></name>
<name><surname>Zhang</surname><given-names>B</given-names></name>
<name><surname>Lim</surname><given-names>SK</given-names></name>
</person-group><article-title>MSC exosome works through a protein-based mechanism of action</article-title><source>Biochem Soc Trans</source><year>2018</year><volume>46</volume><issue>4</issue><fpage>843</fpage><lpage>853</lpage><pub-id pub-id-type="pmid">29986939</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhu</surname><given-names>Q</given-names></name>
<name><surname>Zhao</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Shang</surname><given-names>M</given-names></name>
<etal/>
</person-group><article-title>Protective effects of circulating microvesicles derived from ischemic preconditioning on myocardial ischemia/reperfusion injury in rats by inhibiting endoplasmic reticulum stress</article-title><source>Apoptosis</source><year>2018</year><volume>23</volume><issue>7-8</issue><fpage>436</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">29980896</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>S</given-names></name>
<name><surname>Mishra</surname><given-names>R</given-names></name>
<name><surname>Bigham</surname><given-names>GE</given-names></name>
<name><surname>Wehman</surname><given-names>B</given-names></name>
<name><surname>Khan</surname><given-names>MM</given-names></name>
<name><surname>Xu</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>A deep proteome analysis identifies the complete secretome as the functional unit of human cardiac progenitor cells</article-title><source>Circ Res</source><year>2017</year><volume>120</volume><issue>5</issue><fpage>816</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">27908912</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>B</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
</person-group><article-title>Exosomes derived from mesenchymal stem cells</article-title><source>Int J Mol Sci</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>4142</fpage><lpage>4157</lpage><pub-id pub-id-type="pmid">24608926</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adamiak</surname><given-names>M</given-names></name>
<name><surname>Cheng</surname><given-names>G</given-names></name>
<name><surname>Bobis-Wozowicz</surname><given-names>S</given-names></name>
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Kedracka-Krok</surname><given-names>S</given-names></name>
<name><surname>Samanta</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>Induced pluripotent stem cell (iPSC)-derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs</article-title><source>Circ Res</source><year>2018</year><volume>122</volume><issue>2</issue><fpage>296</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">29118058</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chistiakov</surname><given-names>DA</given-names></name>
<name><surname>Orekhov</surname><given-names>AN</given-names></name>
<name><surname>Bobryshev</surname><given-names>YV</given-names></name>
</person-group><article-title>Cardiac extracellular vesicles in normal and infarcted heart</article-title><source>Int J Mol Sci</source><year>2016</year><volume>17</volume><issue>1</issue><fpage>63</fpage><lpage>63</lpage></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kishore</surname><given-names>R</given-names></name>
<name><surname>Khan</surname><given-names>M</given-names></name>
</person-group><article-title>More than tiny sacks: stem cell exosomes as cell-free modality for cardiac repair</article-title><source>Circ Res</source><year>2016</year><volume>118</volume><issue>2</issue><fpage>330</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">26838317</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallet</surname><given-names>R</given-names></name>
<name><surname>Dawkins</surname><given-names>J</given-names></name>
<name><surname>Valle</surname><given-names>J</given-names></name>
<name><surname>Simsolo</surname><given-names>E</given-names></name>
<name><surname>de Couto</surname><given-names>G</given-names></name>
<name><surname>Middleton</surname><given-names>R</given-names></name>
<etal/>
</person-group><article-title>Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>3</issue><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">28158410</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Sun</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Exosomes derived from Akt-modified human umbilical cord mesenchymal stem cells improve cardiac regeneration and promote angiogenesis via activating platelet-derived growth factor D</article-title><source>Stem Cells Transl Med</source><year>2017</year><volume>6</volume><issue>1</issue><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">28170176</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khan</surname><given-names>M</given-names></name>
<name><surname>Nickoloff</surname><given-names>E</given-names></name>
<name><surname>Abramova</surname><given-names>T</given-names></name>
<name><surname>Johnson</surname><given-names>J</given-names></name>
<name><surname>Verma</surname><given-names>SK</given-names></name>
<name><surname>Krishnamurthy</surname><given-names>P</given-names></name>
<etal/>
</person-group><article-title>Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction</article-title><source>Circ Res</source><year>2015</year><volume>117</volume><issue>1</issue><fpage>52</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">25904597</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mentkowski</surname><given-names>KI</given-names></name>
<name><surname>Lang</surname><given-names>JK</given-names></name>
</person-group><article-title>Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>10041</fpage><lpage>10041</lpage><pub-id pub-id-type="pmid">31296886</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamashita</surname><given-names>T</given-names></name>
<name><surname>Takahashi</surname><given-names>Y</given-names></name>
<name><surname>Takakura</surname><given-names>Y</given-names></name>
</person-group><article-title>Possibility of exosomebased therapeutics and challenges in production of exosomes eligible for therapeutic application</article-title><source>Biol Pharm Bull</source><year>2018</year><volume>41</volume><issue>6</issue><fpage>835</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">29863072</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>T</given-names></name>
<name><surname>Zhang</surname><given-names>HX</given-names></name>
<name><surname>He</surname><given-names>CP</given-names></name>
<name><surname>Fan</surname><given-names>S</given-names></name>
<name><surname>Zhu</surname><given-names>YL</given-names></name>
<name><surname>Qi</surname><given-names>C</given-names></name>
<etal/>
</person-group><article-title>Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy</article-title><source>Biomaterials</source><year>2018</year><volume>150</volume><fpage>137</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">29040874</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Migault</surname><given-names>M</given-names></name>
<name><surname>Donnou-Fournet</surname><given-names>E</given-names></name>
<name><surname>Galibert</surname><given-names>MD</given-names></name>
<name><surname>Gilot</surname><given-names>D</given-names></name>
</person-group><article-title>Definition and identification of small RNA sponges: Focus on miRNA sequestration</article-title><source>Methods</source><year>2017</year><volume>117</volume><fpage>35</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">27876678</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>G</given-names></name>
<name><surname>Huang</surname><given-names>ZP</given-names></name>
<name><surname>Wang</surname><given-names>DZ</given-names></name>
</person-group><article-title>MicroRNAs in cardiac regeneration and cardiovascular disease</article-title><source>Sci China Life Sci</source><year>2013</year><volume>56</volume><issue>10</issue><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">23974704</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shrestha</surname><given-names>S</given-names></name>
<name><surname>Ren</surname><given-names>L</given-names></name>
<name><surname>Vaidya</surname><given-names>R</given-names></name>
</person-group><article-title>miRNAs as biomarkers for diagnosis and assessment of prognosis of coronary artery disease</article-title><source>Open J Intern Med</source><year>2018</year><volume>08</volume><issue>01</issue><fpage>54</fpage><lpage>63</lpage></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samanta</surname><given-names>S</given-names></name>
<name><surname>Balasubramanian</surname><given-names>S</given-names></name>
<name><surname>Rajasingh</surname><given-names>S</given-names></name>
<name><surname>Patel</surname><given-names>U</given-names></name>
<name><surname>Dhanasekaran</surname><given-names>A</given-names></name>
<name><surname>Dawn</surname><given-names>B</given-names></name>
<etal/>
</person-group><article-title>MicroRNA: a new therapeutic strategy for cardiovascular diseases</article-title><source>Trends Cardiovasc Med</source><year>2016</year><volume>26</volume><issue>5</issue><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">27013138</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>K</given-names></name>
<name><surname>Liu</surname><given-names>D</given-names></name>
<name><surname>Lai</surname><given-names>H</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
</person-group><article-title>Developing miRNA therapeutics for cardiac repair in ischemic heart disease</article-title><source>J Thorac Dis</source><year>2016</year><volume>8</volume><issue>9</issue><fpage>E918</fpage><lpage>E927</lpage><pub-id pub-id-type="pmid">27747027</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Shang</surname><given-names>Y</given-names></name>
<name><surname>Dai</surname><given-names>S</given-names></name>
<name><surname>Wu</surname><given-names>W</given-names></name>
<name><surname>Yi</surname><given-names>F</given-names></name>
<name><surname>Cheng</surname><given-names>L</given-names></name>
</person-group><article-title>MicroRNA-16-5p aggravates myocardial infarction injury by targeting the expression of insulin receptor substrates 1 and mediating myocardial apoptosis and angiogenesis</article-title><source>Curr Neurovasc Res</source><year>2020</year><volume>17</volume><issue>1</issue><fpage>11</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">31870262</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Z</given-names></name>
<name><surname>Du</surname><given-names>S</given-names></name>
<name><surname>Shen</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
</person-group><article-title>microRNA-132 inhibits cardiomyocyte apoptosis and myocardial remodeling in myocardial infarction by targeting IL-1&#x003b2;</article-title><source>J Cell Physiol</source><year>2020</year><volume>235</volume><issue>3</issue><fpage>2710</fpage><lpage>2721</lpage><pub-id pub-id-type="pmid">31621911</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bai</surname><given-names>Y</given-names></name>
<name><surname>Bai</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
</person-group><article-title>Sequential delivery of VEGF, FGF-2 and PDGF from the polymeric system enhance HUVECs angiogenesis in vitro and CAM angiogenesis</article-title><source>Cell Immunol</source><year>2018</year><volume>323</volume><fpage>19</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">29111157</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rebou&#x000e7;as</surname><given-names>JS</given-names></name>
<name><surname>Santos-Magalh&#x000e3;es</surname><given-names>NS</given-names></name>
<name><surname>Formiga</surname><given-names>FR</given-names></name>
</person-group><article-title>Cardiac regeneration using growth factors: advances and challenges</article-title><source>Arq Bras Cardiol</source><year>2016</year><volume>107</volume><issue>3</issue><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">27355588</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thavapalachandran</surname><given-names>S</given-names></name>
<name><surname>Grieve</surname><given-names>SM</given-names></name>
<name><surname>Hume</surname><given-names>RD</given-names></name>
<name><surname>Le</surname><given-names>TYL</given-names></name>
<name><surname>Raguram</surname><given-names>K</given-names></name>
<name><surname>Hudson</surname><given-names>JE</given-names></name>
<etal/>
</person-group><article-title>Platelet-derived growth factor-AB improves scar mechanics and vascularity after myocardial infarction</article-title><source>Sci Transl Med</source><year>2020</year><volume>12</volume><issue>524</issue><fpage>eaay2140</fpage><lpage>eaay2140</lpage><pub-id pub-id-type="pmid">31894101</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hajjar</surname><given-names>RJ</given-names></name>
<name><surname>Hulot</surname><given-names>JS</given-names></name>
</person-group><article-title>Myocardial delivery of stromal cell-derived factor 1 in patients with ischemic heart disease: safe and promising</article-title><source>Circ Res</source><year>2013</year><volume>112</volume><issue>5</issue><fpage>746</fpage><lpage>747</lpage><pub-id pub-id-type="pmid">23429606</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Timmers</surname><given-names>L</given-names></name>
<name><surname>Lim</surname><given-names>SK</given-names></name>
<name><surname>Hoefer</surname><given-names>IE</given-names></name>
<name><surname>Arslan</surname><given-names>F</given-names></name>
<name><surname>Lai</surname><given-names>RC</given-names></name>
<name><surname>van Oorschot</surname><given-names>AA</given-names></name>
<etal/>
</person-group><article-title>Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction</article-title><source>Stem Cell Res</source><year>2011</year><volume>6</volume><issue>3</issue><fpage>206</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">21419744</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gunawardena</surname><given-names>TNA</given-names></name>
<name><surname>Rahman</surname><given-names>MT</given-names></name>
<name><surname>Abdullah</surname><given-names>BJJ</given-names></name>
<name><surname>Abu Kasim</surname><given-names>NH</given-names></name>
</person-group><article-title>Conditioned media derived from mesenchymal stem cell cultures: the next generation for regenerative medicine</article-title><source>J Tissue Eng Regen Med</source><year>2019</year><volume>13</volume><issue>4</issue><fpage>569</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">30644175</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yamaguchi</surname><given-names>S</given-names></name>
<name><surname>Shibata</surname><given-names>R</given-names></name>
<name><surname>Yamamoto</surname><given-names>N</given-names></name>
<name><surname>Nishikawa</surname><given-names>M</given-names></name>
<name><surname>Hibi</surname><given-names>H</given-names></name>
<name><surname>Tanigawa</surname><given-names>T</given-names></name>
<etal/>
</person-group><article-title>Dental pulp-derived stem cell conditioned medium reduces cardiac injury following ischemia-reperfusion</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>16295</fpage><lpage>16295</lpage><pub-id pub-id-type="pmid">26542315</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ellison-Hughes</surname><given-names>GM</given-names></name>
<name><surname>Madeddu</surname><given-names>P</given-names></name>
</person-group><article-title>Exploring pericyte and cardiac stem cell secretome unveils new tactics for drug discovery</article-title><source>Pharmacol Ther</source><year>2017</year><volume>171</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">27916652</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>He</surname><given-names>J</given-names></name>
<name><surname>Cai</surname><given-names>Y</given-names></name>
<name><surname>Luo</surname><given-names>LM</given-names></name>
<name><surname>Liu</surname><given-names>HB</given-names></name>
</person-group><article-title>Hypoxic adipose mesenchymal stem cells derived conditioned medium protects myocardial infarct in rat</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2015</year><volume>19</volume><issue>22</issue><fpage>4397</fpage><lpage>4406</lpage><pub-id pub-id-type="pmid">26636529</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yl&#x000e4;-Herttuala</surname><given-names>S</given-names></name>
<name><surname>Bridges</surname><given-names>C</given-names></name>
<name><surname>Katz</surname><given-names>MG</given-names></name>
<name><surname>Korpisalo</surname><given-names>P</given-names></name>
</person-group><article-title>Angiogenic gene therapy in cardiovascular diseases: dream or vision?</article-title><source>Eur Heart J</source><year>2017</year><volume>38</volume><issue>18</issue><fpage>1365</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">28073865</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eibel</surname><given-names>B</given-names></name>
<name><surname>Rodrigues</surname><given-names>CG</given-names></name>
<name><surname>Giusti</surname><given-names>II</given-names></name>
<name><surname>Nesralla</surname><given-names>IA</given-names></name>
<name><surname>Prates</surname><given-names>PRL</given-names></name>
<name><surname>Sant&#x02019;Anna</surname><given-names>RT</given-names></name>
<etal/>
</person-group><article-title>Terapia g&#x000ea;nica para cardiopatia isqu&#x000ea;mica: revis&#x000e3;o de ensaios cl&#x000ed;nicos</article-title><source>BJCVS</source><year>2011</year><volume>26</volume><fpage>635</fpage><lpage>646</lpage><pub-id pub-id-type="pmid">22358281</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lavu</surname><given-names>M</given-names></name>
<name><surname>Gundewar</surname><given-names>S</given-names></name>
<name><surname>Lefer</surname><given-names>DJ</given-names></name>
</person-group><article-title>Gene therapy for ischemic heart disease</article-title><source>J Mol Cell Cardiol</source><year>2011</year><volume>50</volume><issue>5</issue><fpage>742</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">20600100</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Esmaeilzadeh</surname><given-names>A</given-names></name>
<name><surname>Mohammadzadeh</surname><given-names>A</given-names></name>
<name><surname>Bahmaie</surname><given-names>N</given-names></name>
</person-group><article-title>New generation of promising immunotherapeutics approaches for psoriasis dilemma; IL-35 gene as a potentiated candidate</article-title><source>Inflammation and Cell Signaling</source><year>2018</year><volume>5</volume><fpage>e1635</fpage><lpage>e1635</lpage></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Zheng</surname><given-names>H</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>A</given-names></name>
<etal/>
</person-group><article-title>IGF-1 enhances BMSC viability, migration, and anti-apoptosis in myocardial infarction via secreted frizzled-related protein 2 pathway</article-title><source>Stem Cell Res Ther</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>22</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">31918758</pub-id></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Su</surname><given-names>G</given-names></name>
<name><surname>Liu</surname><given-names>L</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Mu</surname><given-names>Y</given-names></name>
<name><surname>Guan</surname><given-names>L</given-names></name>
</person-group><article-title>Homing of endogenous bone marrow mesenchymal stem cells to rat infarcted myocardium via ultrasound-mediated recombinant SDF-1&#x003b1; adenovirus in microbubbles</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>477</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">29416629</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>T</given-names></name>
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Manuel</surname><given-names>G</given-names></name>
<name><surname>Taylor</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>D</given-names></name>
</person-group><article-title>Approaches to therapeutic angiogenesis for ischemic heart disease</article-title><source>J Mol Med (Berl)</source><year>2019</year><volume>97</volume><issue>2</issue><fpage>141</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">30554258</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bauz&#x000e1;</surname><given-names>MDR</given-names></name>
<name><surname>Gim&#x000e9;nez</surname><given-names>CS</given-names></name>
<name><surname>Locatelli</surname><given-names>P</given-names></name>
<name><surname>De Lorenzi</surname><given-names>A</given-names></name>
<name><surname>Hnatiuk</surname><given-names>A</given-names></name>
<name><surname>Capogrossi</surname><given-names>MC</given-names></name>
<etal/>
</person-group><article-title>High-dose intramyocardial HMGB1 induces long-term cardioprotection in sheep with myocardial infarction</article-title><source>Drug Deliv Transl Res</source><year>2019</year><volume>9</volume><issue>5</issue><fpage>935</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">30859393</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hadjizadeh</surname><given-names>A</given-names></name>
<name><surname>Ghasemkhah</surname><given-names>F</given-names></name>
<name><surname>Ghasemzaie</surname><given-names>N</given-names></name>
</person-group><article-title>Polymeric scaffold based gene delivery strategies to improve angiogenesis in tissue engineering: a review</article-title><source>Polym Rev</source><year>2017</year><volume>57</volume><issue>3</issue><fpage>505</fpage><lpage>556</lpage></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>ZQ</given-names></name>
<name><surname>Xing</surname><given-names>WH</given-names></name>
</person-group><article-title>Progress in gene therapy for chronic heart failure</article-title><source>Heart Surg Forum</source><year>2018</year><volume>21</volume><issue>2</issue><fpage>E075</fpage><lpage>E083</lpage><pub-id pub-id-type="pmid">29658862</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Laakkonen</surname><given-names>JP</given-names></name>
<name><surname>Yl&#x000e4;-Herttuala</surname><given-names>S</given-names></name>
</person-group><article-title>Recent advancements in cardiovascular gene therapy and vascular biology</article-title><source>Hum Gene Ther</source><year>2015</year><volume>26</volume><issue>8</issue><fpage>518</fpage><lpage>524</lpage><pub-id pub-id-type="pmid">26192706</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Yue</surname><given-names>F</given-names></name>
<name><surname>Jia</surname><given-names>X</given-names></name>
<etal/>
</person-group><article-title>Stem cellderived extracellular vesicles for myocardial infarction: a metaanalysis of controlled animal studies</article-title><source>Aging (Albany NY)</source><year>2019</year><volume>11</volume><issue>4</issue><fpage>1129</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">30792374</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Hu</surname><given-names>J</given-names></name>
<name><surname>Fu</surname><given-names>B</given-names></name>
<name><surname>Mao</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<etal/>
</person-group><article-title>Extracellular vesicles for acute kidney injury in preclinical rodent models: a meta-analysis</article-title><source>Stem Cell Res Ther</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>11</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">31900218</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willis</surname><given-names>GR</given-names></name>
<name><surname>Kourembanas</surname><given-names>S</given-names></name>
<name><surname>Mitsialis</surname><given-names>SA</given-names></name>
</person-group><article-title>Toward exosome-based therapeutics: isolation, heterogeneity, and fit-for-purpose potency</article-title><source>Front Cardiovasc Med</source><year>2017</year><volume>4</volume><fpage>63</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">29062835</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meng</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>B</given-names></name>
<name><surname>Tao</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Weizhu</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Safety and efficacy of adenovirus carrying hepatocyte growth factor gene by percutaneous endocardial injection for treating post-infarct heart failure: a phase iia clinical trial</article-title><source>Curr Gene Ther</source><year>2018</year><volume>18</volume><issue>2</issue><fpage>125</fpage><lpage>130</lpage><pub-id pub-id-type="pmid">29618307</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gross</surname><given-names>L</given-names></name>
<name><surname>Theiss</surname><given-names>HD</given-names></name>
<name><surname>Grabmaier</surname><given-names>U</given-names></name>
<name><surname>Adrion</surname><given-names>C</given-names></name>
<name><surname>Mansmann</surname><given-names>U</given-names></name>
<name><surname>Sohn</surname><given-names>HY</given-names></name>
<etal/>
</person-group><article-title>Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction - Long-term results of the SITAGRAMI trial</article-title><source>Int J Cardiol</source><year>2016</year><volume>215</volume><fpage>441</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">27131268</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuku&#x00142;a</surname><given-names>K</given-names></name>
<name><surname>Urbanowicz</surname><given-names>A</given-names></name>
<name><surname>K&#x00142;opotowski</surname><given-names>M</given-names></name>
<name><surname>D&#x00105;browski</surname><given-names>M</given-names></name>
<name><surname>Pr&#x00119;gowski</surname><given-names>J</given-names></name>
<name><surname>K&#x00105;dziela</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGFA165/ bFGF cDNA for the treatment of refractory coronary artery disease</article-title><source>Am Heart J</source><year>2019</year><volume>215</volume><fpage>78</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">31288177</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anttila</surname><given-names>V</given-names></name>
<name><surname>Saraste</surname><given-names>A</given-names></name>
<name><surname>Knuuti</surname><given-names>J</given-names></name>
<name><surname>Jaakkola</surname><given-names>P</given-names></name>
<name><surname>Hedman</surname><given-names>M</given-names></name>
<name><surname>Svedlund</surname><given-names>S</given-names></name>
<etal/>
</person-group><article-title>Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial</article-title><source>Mol Ther Methods Clin Dev</source><year>2020</year><volume>18</volume><fpage>464</fpage><lpage>472</lpage><pub-id pub-id-type="pmid">32728595</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Greenberg</surname><given-names>B</given-names></name>
<name><surname>Butler</surname><given-names>J</given-names></name>
<name><surname>Felker</surname><given-names>GM</given-names></name>
<name><surname>Ponikowski</surname><given-names>P</given-names></name>
<name><surname>Voors</surname><given-names>AA</given-names></name>
<name><surname>Desai</surname><given-names>AS</given-names></name>
<etal/>
</person-group><article-title>Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial</article-title><source>Lancet</source><year>2016</year><volume>387</volume><issue>10024</issue><fpage>1178</fpage><lpage>1186</lpage><pub-id pub-id-type="pmid">26803443</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>ES</given-names></name>
<name><surname>Miller</surname><given-names>L</given-names></name>
<name><surname>Patel</surname><given-names>AN</given-names></name>
<name><surname>Anderson</surname><given-names>RD</given-names></name>
<name><surname>Mendelsohn</surname><given-names>FO</given-names></name>
<name><surname>Traverse</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cellderived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized phase II trial</article-title><source>Eur Heart J</source><year>2015</year><volume>36</volume><issue>33</issue><fpage>2228</fpage><lpage>2238</lpage><pub-id pub-id-type="pmid">26056125</pub-id></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Penn</surname><given-names>MS</given-names></name>
<name><surname>Mendelsohn</surname><given-names>FO</given-names></name>
<name><surname>Schaer</surname><given-names>GL</given-names></name>
<name><surname>Sherman</surname><given-names>W</given-names></name>
<name><surname>Farr</surname><given-names>M</given-names></name>
<name><surname>Pastore</surname><given-names>J</given-names></name>
<etal/>
</person-group><article-title>An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure</article-title><source>Circ Res</source><year>2013</year><volume>112</volume><issue>5</issue><fpage>816</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">23429605</pub-id></element-citation></ref></ref-list></back></article>
